deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT03541902

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Cabosun Ii: Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma

Sponsor: Exelixis

Conditions Chromophobe Renal Cell Carcinoma Malignant Neoplasms of Urinary Tract Metastatic Renal Cell Carcinoma Papillary Renal Cell Carcinoma Renal Cell Carcinoma Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions Sarcomatoid Renal Cell Carcinoma Stage IV Renal Cell Cancer AJCC v8 Unclassified Renal Cell Carcinoma
Interventions Cabozantinib Sunitinib Malate
Updated 16 times since 2018 Last updated: Jan 7, 2026 Started: May 15, 2018 Primary completion: Jul 31, 2027 Completion: Jul 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chromophobe Renal Cell Carcinoma and Malignant Neoplasms of Urinary Tract and is currently ongoing. Exelixis leads this study, which shows 16 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~May 2019 · 8 months · monthly snapshot~May 2019 – ~Jul 2020 · 14 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Jul 2022 · 17 months · monthly snapshot~Jul 2022 – ~Jan 2023 · 6 months · monthly snapshot~Jan 2023 – ~Jul 2023 · 6 months · monthly snapshot~Jul 2023 – ~Jan 2024 · 6 months · monthly snapshot~Jan 2024 – ~Jun 2024 · 5 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Feb 2026 · 12 months · monthly snapshot~Feb 2026 – present · 7 months · monthly snapshot

Change History

16 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Feb 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 11 earlier versions

  1. Jan 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Jul 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Feb 2021 — Jul 2022 [monthly]

    Recruiting PHASE2

  6. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  7. Jul 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  8. May 2019 — Jul 2020 [monthly]

    Recruiting PHASE2

  9. Sep 2018 — May 2019 [monthly]

    Recruiting PHASE2

  10. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  11. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

    First recorded

May 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Exelixis
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations